XIAP and head and neck squamous cell carcinoma: A new double-blind, randomized phase 2 clinical study by Jean and colleagues showed that Xevinapant (a novel potent small-molecule IAP antagonist that inhibits XIAP and cIAP1/2) plus RT reduced the risk of death by more than half compared to placebo plus RT in patients with unresectable, locally advanced HNSCC, while not increasing toxicity.